Recent Updates
Recently added Catalysts

Kalaris Therapeutics, Inc.

KLRSFDA catalysts, PDUFA dates & pipeline intelligence
$1.28
▼ -0.07 · -5.19%

Financials

Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Quarterly Cash
Unlock full KLRS financials and dilution scoring
Quarter by quarter figures, cash trend and dilution risk.
Institutional-grade data · Cancel anytime
52W LOW $1.2552W HIGH $11.88
Volume
37.99 K
Value Traded
50.20 K
Short % Float
4.24%
Days to Cover
5.4
-18.73%Week
-36.63%1 Month
-69.16%3 Month
-73.98%6 Month
-81.45%1 Year
-88.84%All Time

Cash Data

Unlock KLRS cash and runway
  • Monthly Burn
  • Burn Trend
  • Dilution Risk
  • SEC Filing

Key Stats

Market Cap
30.47 M
EPS (TTM)
-1.88
P/E Ratio
-
Ent. Value
-52.39 M
Total Shares
23.80 M
Float Shares
8.64 M
Insiders
63.69%
Institutions
22.44%

Upcoming Catalysts

FDA decisions, readouts and PDUFA dates · scored by probability of approval

Catalyst Drug / Treatment Stage Prob. of Approval Description Drug Type Therapeutic Area Source
Phase 1b/2 data readout
TH103
neovascular age-related macular degeneration (nAMD)
Phase 1b/2BiologicsOphthalmology
Unlock every KLRS catalyst date and PoA score
Every FDA decision, readout and PDUFA date, with drug type, therapeutic area and a PoA score you can trade on.
Institutional-grade data · Cancel anytime
PoA blends historical approval base rates, trial design score and FDA review track record.

KLRS Catalyst Timeline

Dated clinical, regulatory and corporate events for Kalaris Therapeutics, Inc.

Catalyst Timeline

Dated clinical, regulatory & corporate events for Kalaris Therapeutics, Inc.

47Total events
8Upcoming
15Tier-1 (high impact)
2024 to 2028Coverage

Upcoming catalysts 2

T2Trial Initiation
Subscribe to view catalyst details
TH103
T1Topline Readout
Subscribe to view catalyst details
TH103

Event history 37

●Quarterly UpdateCorporate
Kalaris reports third quarter 2026 financial results and business update
●Quarterly UpdateCorporate
Second quarter 2026 financial results reported
●Enrollment UpdateTH103Trial
Patient dosing ongoing in Phase 1b/2 study of TH103
●Enrollment UpdateTH103Trial
Kalaris continues to enroll and dose nAMD patients in Phase 1b/2 study of TH103
neovascular age-related macular degeneration (nAMD)source ↗
▼Supply DisruptionTH103CMC / Inspection
Pilot manufacturer batch of TH103 failed release specification for aggregation
neovascular age-related macular degeneration (nAMD)source ↗
▲Manufacturing MilestoneTH103CMC / Inspection
Completed tech transfer to KBI Biopharma commercial-scale manufacturer; test batches met target specifications
●Runway Guidance UpdateCorporate
Cash runway guidance
◆Enrollment UpdateTH103Trial
Patient screening underway in Phase 1b/2 study of TH103
neovascular Age-related Macular Degenerationsource ↗
●Manufacturing MilestoneTH103CMC / Inspection
Latest drug product batch on track to be available to support upcoming dosing
neovascular Age-related Macular Degenerationsource ↗
●Quarterly UpdateCorporate
First quarter 2026 financial results reported
Unlock the full KLRS catalyst timeline
Every PDUFA date, readout, approval and corporate move, tiered by market impact and updated daily.
Institutional-grade data · Cancel anytime

Past FDA Catalysts and PDUFA Decisions

How KLRS actually traded into and out of each decision

Date Drug Catalyst Stage Reaction Event Move % Best Trade %
2025-12-17TH103 Phase 1a data readout Phase 1a
Unlock all KLRS historical catalysts
Institutional-grade data · Cancel anytime
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision

Drug Pipeline Intelligence

Pipeline Score
Pipeline Value
Valuation Signal
1
Drugs Scored
rNPV / MCap
Top Drug
Top 69%
Micro Cap
(rank 496 of 719)
Percentile Rank
Showing 2 of 4 assets
DrugIndicationPhasePTRSrNPVStatusEnrollVelocityDesignEst. CompletionML SignalLast Change
Posoleucel Cell TherapiesCompletedNCT04693637Adenovirus InfectionPhase 2/3 COMPLETED 26Jan 19, 2023
Posoleucel cells Cell TherapiesCompletedNCT04605484BK Virus NephropathyPhase 2 COMPLETED 61Oct 20, 2022
Unlock the KLRS pipeline intelligence model
PTRS, rNPV, enrollment velocity, trial design quality and ML risk signals for every asset above.
Institutional-grade data · Cancel anytime

Clinical Trial Results

Readouts, endpoints and source filings for every KLRS program

Drug Name Indication Phase Date Trial Results SummaryTitleSource
TH103 neovascular AMDPhase 1a2025-12-17mean 10-letter gain in visual acuityRead MoreKalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Na ve Neovascular AMD TH103 showed mean 10-letter gain in visual acuity and rapid, robust anatomic improvement at Month 1, following a siRead More
Scroll for more · summaries link to the source press release
Unlock every KLRS trial readout
Institutional-grade data · Cancel anytime

Inside Trades

Unlock KLRS insider buying and selling
Monthly insider buys and sells against the stock price, with the insider sentiment reading.
Institutional-grade data · Cancel anytime
InsiderSideSharesPriceValueDate
AKKARAJU SRINIVASDirector, 10% OwnerBuy 244,300 2,224,147 held$4.83 05/20/2026
Unlock the full KLRS insider trade log
Institutional-grade data · Cancel anytime

Hedge Fund 13F Activity

Fund % of Portfolio Current MV Shares Owned Activity
Samsara BioCapital, LLC 3.5 % (-18.6 %) 37.23 M 12.88 M
Unlock every fund holding KLRS
Every 13F position with quarter over quarter share flow and average entry price.
Institutional-grade data · Cancel anytime
Unlock hedge fund flows in KLRS
Shares held by hedge funds each quarter, and who bought or sold.

Ownership Trends

Sign in to see KLRS ownership
Insider and institutional ownership, quarter by quarter.

KLRS Short Interest

Shares sold short, counted twice a month.

4.24%
Short % of Float
of tradable shares sold short
366.6K
Shares Sold Short
+19.7% vs prior count
5.4 High
Days to Cover
trading days of normal volume to buy every short share back
67.6K
Avg Daily Volume
the average used for days to cover
Unlock KLRS short interest history
Two years of days to cover and shares sold short, with every count and its change.
Institutional-grade data · Cancel anytime

Options Data

Option Volume

Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg

Option Chain Statistics

ExpiryCall VolPut VolVol P/CCall OIPut OIOI P/CIV CallIV Call OI-WtdIV Call Vol-WtdIV PutIV Put OI-WtdIV Put Vol-Wtd
Unlock KLRS option chain statistics
Per-expiry call and put volume, open interest, put-call ratios and implied volatility.
Institutional-grade data · Cancel anytime

Real-Time Option Chain

CallsStrikePuts
LastVolOILastVolOI
No data available
Unlock the live KLRS option chain
Live calls and puts by strike: last price, volume and open interest for every expiry.
Institutional-grade data · Cancel anytime

Calls vs Puts by Expiry

CallsPutsLog scale
Unlock KLRS options analytics
Institutional-grade data · Cancel anytime

Competitive positioning

How KLRS ranks across every disease it competes in

Competitive Position is a premium feature
See how KLRS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial

KLRS News

KLRS
Nov 10, 2026
KLRSGeneral
▼ -18.7%on this news· ran to -32% by day 3

Kalaris Reports Third Quarter 2026 Financial Results and Provides Business Update

Kalaris Therapeutics reported its Q3 2026 financial results, highlighting a successful technology transfer to a commercial-scale manufacturer. The ongoing Phase 1b/2 study of TH103 in neovascular age-related macular degeneration (nAMD) is experiencing delays, with preliminary data now expected in 2H 2027. The company has $82.9 million in cash, projected to fund operations into 2028.

Read more →
KLRS
Aug 31, 2026
KLRSConferences/Events

Kalaris to Present at Morgan Stanley 24th Annual Global Healthcare Conference

Kalaris Therapeutics announced that its management team will participate in a Fireside Chat at the Morgan Stanley 24th Annual Global Healthcare Conference. The session is scheduled for Tuesday, September 15, 2026, in New York. Chief Executive Officer Andrew Oxtoby and Chief Medical Officer Matthew Feinsod will lead the discussion. Kalaris is currently developing TH103 for neovascular Age-related Macular Degeneration.

Read more →
KLRS
Aug 11, 2026
KLRSPhases

Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates

Kalaris Therapeutics reported a net loss of $11.5 million for the second quarter ended June 30, 2026. The company held $93.5 million in cash and marketable securities at the end of the period. This balance is expected to fund operations through the fourth quarter of 2027. Patient dosing is ongoing in the Phase 1b/2 study of TH103 for neovascular AMD.

Read more →
KLRS
Jul 20, 2026
KLRSGeneral
▼ -8.7%on this news

Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer

Kalaris Therapeutics appointed Liisa Bayko as chief financial officer. She brings over twenty years of biotechnology finance experience to the role. The hire supports the company as it advances its Phase 1b/2 study of TH103. This trial targets treatment naïve patients with neovascular age-related macular degeneration.

Read more →
KLRS
Jul 17, 2026
KLRSPhases

Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts

Kalaris Therapeutics reported positive Phase 1a data for TH103 in neovascular AMD. The drug showed extended intraocular retention with 27- to 53-fold lower Cmax than current anti-VEGF agents. Forty-one percent of treatment-naive patients required no retreatment for four months or longer. Enrollment in the Phase 1b/2 trial continues, with preliminary data expected in the first half of 2027.

Read more →
KLRS
Jul 6, 2026
KLRSGeneral

Kalaris Appoints Laurie Keating to Board of Directors

Kalaris Therapeutics appointed Laurie Keating to its board of directors effective August 1, 2026. Morana Jovan-Embiricos stepped down from the board at the same time. Keating brings experience from roles at Alnylam Pharmaceuticals and current board positions at PepGen and Immuneering. The company continues developing TH103 for retinal diseases.

Read more →
KLRS
Jun 23, 2026
KLRSPhases

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics will present Phase 1a data for TH103 at the American Society of Retina Specialists meeting on July 17, 2026. The company also confirmed that its Phase 1b/2 trial for neovascular Age-related Macular Degeneration is actively enrolling and dosing patients. Initial results from this ongoing study are expected in the first half of 2027. These updates support the drug’s development path toward potential Phase 3 trials.

Read more →
KLRS
Jun 12, 2026
KLRSConferences/Events

Kalaris to Present at Clinical Trials at the Summit 2026

Kalaris Therapeutics will present Phase 1a clinical data for TH103 at the Clinical Trials at the Summit 2026. The data focuses on treatment-naïve patients with Neovascular Age-Related Macular Degeneration. The presentation will be led by Dr. Karl Csaky and is scheduled for June 13, 2026, in Las Vegas, NV.

Read more →
KLRS
May 12, 2026
KLRSPhases

Kalaris Reports First Quarter 2026 Financial Results and Provides Business Updates Patient screening now underway in the Phase 1b/2 study with the latest drug product batch on track to be

Kalaris Therapeutics, Inc. reported its financial results for the first quarter of 2026 and provided business updates. The company is currently screening patients in its Phase 1b/2 study for the drug TH103, aimed at treating neovascular Age-related Macular Degeneration, with preliminary data expected in the first half of 2027. Kalaris has $104.9 million in cash reserves, projected to fund operations through late 2027, while planned Phase 3 trials are slated for initiation by year-end 2027. However, a continued net loss and rising operational costs were noted in the financial report.

Read more →
KLRS
Mar 17, 2026
KLRSPhases

Kalaris Reports Full Year 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics reported positive initial data from its Phase 1a trial for TH103, aimed at treating neovascular age-related macular degeneration (nAMD), and announced financial results for 2025. The company completed a $50 million private placement and expects its cash reserves will fund operations into the fourth quarter of 2027. While research and development expenses decreased, general administrative expenses rose sharply. Additionally, the net loss for the year was significantly lower than the previous year.

Read more →
KLRS
Mar 9, 2026
KLRSPhases

Forward-Looking Statements & Disclaimer This presentation contains "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange A

Kalaris has provided insights into its forward-looking plans related to its lead drug candidate TH103, intended for retinal diseases. The company has outlined a timeline for clinical trials, however, it warns of various risks and uncertainties inherent to the development process. Additionally, Kalaris indicated it has sufficient cash resources to fund operations into late 2027, following a successful private placement. The drug TH103, which has shown initial promise, aims to address significant unmet medical needs in the market for retinal treatments.

Read more →
KLRS
Jan 28, 2026
KLRSConferences/Events

Kalaris to Present Phase 1 Clinical Data for TH103 at the Macula Society Annual Meeting

Kalaris Therapeutics will present Phase 1 clinical data for TH103 at the Macula Society Annual Meeting from February 25-28, 2026. The therapy, engineered for enhanced VEGF inhibition, targets treatment-naive patients with neovascular age-related macular degeneration. Key details include safety and efficacy outcomes from the study, presented by Dr. Dean Eliott.

Read more →
KLRS
Dec 17, 2025
KLRSPhases

Kalaris Therapeutics Reports Positive Initial Phase 1a Data for TH103 in Treatment-Naïve Neovascular AMD

Kalaris Therapeutics reported positive initial Phase 1a data for TH103 in treatment-naïve patients with neovascular AMD. The data showed significant improvements in visual acuity and retinal anatomy after a single injection. TH103 demonstrated a favorable safety profile, with no serious adverse events reported. The company plans to accelerate its clinical development program based on these results.

Read more →
KLRS
Dec 17, 2025
KLRSPhases
▲ +20.3%on this news

Kalaris Therapeutics Reports Initial Positive Phase 1a Data for TH103 in Treatment-Naïve TH103 showed mean 10-letter gain in visual acuity and rapid, robust

Kalaris Therapeutics reported promising initial data from its Phase 1a study of TH103, indicating significant improvements in visual acuity and retinal anatomy in treatment-naive neovascular AMD patients. The treatment showed a mean gain of 10 letters in visual acuity at Month 1 and was generally well tolerated, prompting plans for further dose escalation. Moreover, a notable pharmacokinetic profile suggested enhanced intraocular retention, which may lead to extended treatment durability. Expected preliminary data from the ongoing Phase 1b/2 study is anticipated in the second half of 2026.

Read more →
KLRS
Dec 17, 2025
KLRSGeneral
▲ +20.3%on this news

Kalaris Therapeutics Announces Oversubscribed $50.0 Million Private Placement

Kalaris Therapeutics has announced an oversubscribed private placement that will raise approximately $50 million. The offering, involving both new and existing institutional investors, is set to close soon and will be used to advance the clinical development of TH103 for neovascular AMD, alongside other corporate purposes. The securities will not be registered under the Securities Act, necessitating a registration rights agreement with the investors.

Read more →
KLRS
Nov 12, 2025
KLRSPhases

Kalaris Reports Third Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics reported its financial results for Q3 2025, highlighting significant corporate milestones and progress in clinical trials. The Phase 1a Single Ascending Dose trial remains on schedule for initial data by year's end, while the Phase 1b/2 trial is currently enrolling participants. The company has substantial cash reserves of $77 million, projected to fund operations into 2027 even as R&D expenses reflect past obligations. Despite a notable net loss, the company is advancing its investigational treatment TH103 aimed at retinal diseases.

Read more →
KLRS
Nov 3, 2025
KLRSGeneral

Kalaris Expands Leadership Team Appointing Matthew Gall, MBA, as Chief Financial Officer

Kalaris Therapeutics appointed Matthew Gall as Chief Financial Officer to enhance its leadership team. Gall, with a strong background in biopharma finance, will support the company's growth as it progresses its Phase 1b/2 study for treatment-naïve nAMD patients. His previous experience includes roles at iTeos Therapeutics and Sarepta Therapeutics.

Read more →
KLRS
Oct 30, 2025
KLRSConferences/Events

Kalaris to Present at Stifel 2025 Annual Healthcare Conference

Kalaris Therapeutics will present at the Stifel 2025 Annual Healthcare Conference on November 13, 2025. CEO Andrew Oxtoby and CMO Matthew Feinsod will speak from 3:20 to 3:50 PM ET. The company aims to address major unmet needs in retinal disease treatments. One-on-one meetings will also be available during the event.

Read more →
KLRS
Sep 15, 2025
KLRSPhases

UPDATE – Kalaris Therapeutics Now Enrolling Phase 1b/2 Multiple Ascending Dose Study of TH103 in Neovascular Age-Related Macular Degeneration

Kalaris Therapeutics has begun enrolling patients for a Phase 1b/2 study of TH103, targeting neovascular age-related macular degeneration (nAMD). This study aims to assess safety and efficacy with four monthly doses of TH103. Initial data is anticipated in the second half of 2026, building on findings from an ongoing Phase 1a study.

Read more →
KLRS
Aug 13, 2025
KLRSPhases
▼ -8.4%on this news

Kalaris Reports Second Quarter 2025 Financial Results and Provides Business Updates

Kalaris Therapeutics reported its financial results for Q2 2025, highlighting a net loss of $11.4 million, a significant increase from the previous year. The company continues to enroll patients in a Phase 1 trial for its new anti-VEGF agent, TH103, with initial data expected by Q4 2025. Kalaris currently holds $88.4 million in cash, which is projected to sustain operations through Q4 2026. The upward trend in R&D and administrative expenses indicates growing operational complexities as the company advances its clinical programs.

Read more →

About Kalaris Therapeutics, Inc.

Berkeley Heights, NJ 20 employees kalaristx.com
Headquarters400 CONNELL DRIVE, BERKELEY HEIGHTS, NJ, 07922
BIOPHARMAWATCH ELITE
Trade the next KLRS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $24/mo billed annually.
Cancel anytime